60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Short Interest Update

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 107,275 shares, a decrease of 49.0% from the January 29th total of 210,488 shares. Approximately 10.3% of the shares of the stock are short sold. Based on an average trading volume of 404,658 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 404,658 shares, the short-interest ratio is presently 0.3 days. Approximately 10.3% of the shares of the stock are short sold.

60 Degrees Pharmaceuticals Trading Down 3.6%

Shares of NASDAQ SXTP opened at $2.96 on Friday. 60 Degrees Pharmaceuticals has a 12-month low of $1.36 and a 12-month high of $17.68. The firm’s 50-day moving average price is $3.14 and its 200-day moving average price is $4.44. The stock has a market capitalization of $3.14 million, a price-to-earnings ratio of -0.21 and a beta of 2.94.

Analysts Set New Price Targets

A number of research analysts recently commented on SXTP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, December 29th. HC Wainwright lifted their price objective on shares of 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Ascendiant Capital Markets dropped their target price on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating for the company in a research report on Friday, November 28th. Finally, Zacks Research raised shares of 60 Degrees Pharmaceuticals to a “hold” rating in a research note on Tuesday, November 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $17.60.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.